Overview

Characterizing LAM With 11C-Choline PET/CT

Status:
Not yet recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
It was reported that TSC2-deficient cells enhance phosphatidylcholine synthesis via the Kennedy pathway. 11C-Choline can reflect the metabolic process of choline in vivo by intravenous injection. The purpose of this study is the ability of 11C-Choline PET/CT to evaluate the baseline condition of LAM patients and the efficacy of rapamycin after treatment.
Phase:
Early Phase 1
Details
Lead Sponsor:
Peking Union Medical College Hospital
Treatments:
Choline